Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,217,199 papers from all fields of science
Search
Sign In
Create Free Account
Bu-Fei-Yi-Shen
Known as:
bufei yishen
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Drugs, Chinese Herbal
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
Jiansheng Li
,
Jindi Ma
,
+10 authors
Dian Zhao
Journal of Ethnopharmacology
2020
Corpus ID: 216647578
2016
2016
System biology analysis of long-term effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profiling
Jiansheng Li
,
Peng Zhao
,
Liping Yang
,
Ya Li
,
Yange Tian
,
Suyun Li
Scientific Reports
2016
Corpus ID: 13042955
System pharmacology identified 195 potential targets of Bufei Yishen formula (BYF) and BYF was proven to have a short-term…
Expand
2016
2016
Bufei Yishen granules combined with acupoint sticking therapy suppress oxidative stress in chronic obstructive pulmonary disease rats: Via regulating peroxisome proliferator-activated receptor-gamma…
Ya Li
,
Yange Tian
,
+7 authors
Shan Luo
Journal of Ethnopharmacology
2016
Corpus ID: 206031405
2016
2016
Effects of Yishen Pinggan Recipe on Renal Protection and NF-κB Signaling Pathway in Spontaneously Hypertensive Rats
Guodong Luo
,
Xiying Zhu
,
+5 authors
Longmin Liu
Evidence-Based Complementary and Alternative…
2016
Corpus ID: 25585686
Inflammation is an important etiological factor of hypertensive renal damage. The effects of Yishen Pinggan Recipe (YPR) on urine…
Expand
2015
2015
Identification of Metabolites and Metabolic Pathways Related to Treatment with Bufei Yishen Formula in a Rat COPD Model Using HPLC Q-TOF/MS
Liping Yang
,
Jiansheng Li
,
+5 authors
Xuekun Song
Evidence-Based Complementary and Alternative…
2015
Corpus ID: 6201800
As a traditional Chinese medicine, Bufei Yishen Formula (BYF) is widely used in China as an effective treatment for chronic…
Expand
2015
2015
Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4…
W. Mao
,
Lei Zhang
,
+19 authors
Xusheng Liu
BMC Complementary and Alternative Medicine
2015
Corpus ID: 3217099
BackgroundChronic kidney disease (CKD) is a global public health problem. Currently, as for advanced CKD populations, medication…
Expand
2014
2014
Long-term effects of three Tiao-Bu Fei-Shen therapies on NF-κB/TGF-β1/smad2 signaling in rats with chronic obstructive pulmonary disease
Ya Li
,
Jian-sheng Li
,
+5 authors
Ying Wang
BMC Complementary and Alternative Medicine
2014
Corpus ID: 1108055
BackgroundThe three Tiao-Bu Fei-Shen (Bufei Jianpi, Bufei Yishen, Yiqi Zishen) granules have been confirmed for their beneficial…
Expand
2012
2012
Long-term effects of Tiaobu Feishen therapies on systemic and local inflammation responses in rats with stable chronic obstructive pulmonary disease.
Jian-sheng Li
,
Ya Li
,
+5 authors
Ying Wang
Zhong xi yi jie he xue bao = Journal of Chinese…
2012
Corpus ID: 36619306
OBJECTIVE To evaluate the influence and long-term effects on systemic and local inflammation responses in rat with stable chronic…
Expand
2011
2011
Yishen Tiaoan Acupuncture Therapy in the Treatment of Perimenopausal Depression:An Observation of 30 Cases
Zou Wei
2011
Corpus ID: 76080879
Objective:To observe the curative effect of Yishen Shugan acupuncture therapy in the treatment of perimenopausal depression.To…
Expand
2010
2010
Effects of Yishen juanbi (YJB) pill on experimental rheumatoid arthritis.
P. Perera
,
C. Peng
,
Xue Lv
,
Yunman Li
,
W. Fang
,
Caifeng Han
2010
Corpus ID: 93134364
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE